Lonza Expands Cell-Culture Portfolio with Quasi Vivo® System

Today Lonza announced the latest addition to its cell-culture product portfolio – the Quasi Vivo® System. The Quasi Vivo® Device consists of an advanced, interconnected fluidics system to create more physiologically relevant cell-culture conditions, helping researchers improve the predictive value of their studies. This new product offering from Lonza is a result of a worldwide marketing and distribution agreement with Kirkstall – a biotechnology company based in Rotherham (UK).

A common issue faced by drug discovery scientists who use conventional in vitro culture systems is their poor translatability to humans. To address this problem, Kirkstall developed the Quasi Vivo® System, which consists of interconnected cell-culture chambers and a peristaltic pump to create a continuous flow of media over cells. As a result, cultures are exposed to more physiologically relevant conditions, increasing the predictive value of in vitro experiments.

The Quasi Vivo® System is available with three different culture chambers...